

Transforming Research to Reality. Advancing Human Health.

Translational Medicine Conference 2022 'Narrowing the Void'

MEDICAL TECHNOLOGY PANEL: 10:15 AM - 11:30 AM

Dr Siobhan Kelleher

Chief Executive Officer, Sision Medical and Principal Investigator, National University of Ireland Galway



Siobhán has over 20 years senior leadership experience in the areas of clinical trials (ICON PIc.), business development and marketing in leading multinationals (Novartis, Wyeth and MSD). She has a unique education spanning scientific (BSc; MSc in Cell Biology and PhD in Pharmacology, UCD), clinical (MSc in Health Policy and Health Services Management, TCD) and commercial (Smurfit PGC; Biolnnovate PG. Dip) training. Siobhán is passionate about health and wellbeing and the ability of food, medicine, and technological innovation to save and improve the lives of patients and their families. To this end, Siobhán completed Biolnnovate, a needs-led innovation programme aligned with Stanford Biodesign. Following clinical immersion in the Mayo clinic (Rochester), she pursued an unmet clinical need in foetal monitoring and secured Marie Sklodowska-Curie and Infant funding for ongoing research in the Translational Medical Device Laboratory in NUI Galway. Siobhán is currently leading projects funded by Enterprise Ireland, Science Foundation Ireland and the European Research Commission to develop a novel digital biomarker to diagnose, monitor and treat chronic inflammatory endocrine conditions such as endometriosis.

Dr Andrew Cameron

Founder and Chief Executive Officer, FeelTect

Dr. Cameron is Founder and CEO of FeelTect, a Galway-based start-up company developing Tight Alright - the first wearable, connected-health technology for measuring and monitoring sub-bandage pressure during compression therapy for venous leg ulcer treatment. He identified the unmet clinical need for Tight Alright during his time as a Fellow in the BioInnovate Ireland programme and has driven the technology's development from concept to clinical studies. He previously worked as a Commercialisation Lead at Royal College of Surgeons in Ireland, supporting the innovation pathways for several medical technologies. Here, he also worked as Research Fellow in the Tissue Engineering Research Group, primarily working on clinical corneal regeneration applications. His education qualifications include an Engineering degree, double majoring in Chemical and Biological Engineering, a PhD in Tissue Engineering, a Graduate Certificate in Research Commercialisation, a Diploma in BioInnovation, and he is currently completing a Higher Diploma in Computer Science.

Mr Gavin Andrews

Co-Founder, Syntropy and Managing Director, HeartMath UK

Gavin Andrews is Managing Director for HeartMath in the UK and Ireland. HeartMath is a system of breathwork, self-regulation techniques and biofeedback technology. Gavin discovered HeartMath, coherence practice and heart-based living 15 years ago. Since then, he has found joy, meaning and purpose in sharing the science and practice of coherence with others. In addition to sharing the benefits of coherence practice through HeartMath, Gavin also founded WeAddHeart, a growing international heart-focused meditation movement. Gavin is passionate about finding practical ways to help people discover calm, clarity and mental and physical balance in our increasingly chaotic and stressed-out world. Recently he co-launched Syntropy, a start-up app which presents beautiful video artworks for breathwork, relaxation and meditation. Prior to his involvement in HeartMath, Gavin

had careers in the newspaper industry, as a business school lecturer and as a leadership coach and trainer.

Mr Stefan McDonald

Chief Growth Officer, Diaceutics

Stefan McDonald is Chief Growth Officer of Diaceutics, a global Precision Medicine who provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX – The Diagnostic Network DXRX is the world's first diagnostic commercialization platform for Precision Medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories. Stefan qualified as a Pharmacist from Robert Gordon University, Aberdeen in 2002 and spent the early part of his career working in clinical and community Pharmacy setting understanding the impact of clinical intervention and medicines on patient outcome and striving to develop patient centred models of care. Following a number of years as a Pharmacy contractor, Stefan further developed his experience by gaining a Masters in Procurement, logistics and Supply chain where he was exposed to the actionable insight that can be derived from the application of real time data. Passion to drive actionable insight in a clinical setting through data took Stefan to work for Optum (US Health Services & Innovation company) serving as a Pharmacist, Business and Product lead and a key member of their Senior Leadership team. Stefan joined as Head of the Labs Team and has been instrumental in the launch of DXRX - The Diagnostic Network® the world's first diagnostic commercialization platform for Precision Medicine, integrating multiple pipelines of real-world diagnostic testing data from Diaceutics global network of laboratories. Progressing to his current role as Chief Growth Officer in 2021 Stefan provides leadership to drive organisation wide growth with a focus on further development of the DXRX platform, expansion of the Global lab Network, Tech enabled and Implementation services. As Chief Growth Officer, Stefan works cross functionally to promote operational efficiency and cohesion within the organisation, acting as a catalyst to drive cultural and organizational change. As part of his role as Chief Growth Officer, Stefan hopes to continue to invest in the right talent and people who share the same vision of 'Better Testing, Better Treatment' and to further drive the success and growth of Diaceutics. Through the Diaceutics Graduate Program newly graduated life sciences students gain the opportunity to come and work with us to solve industry challenges and join a vibrant and growing company.

KEYNOTE SPEAKER: 12:00 PM - 13:00 PM

Professor Walter Kolch

Director of Systems Biology Ireland and Precision Oncology

Walter Kolch is Director of Systems Biology Ireland (https://www.ucd.ie/sbi/) and the Precisid Oncology Ireland Consortium (https://www.precisiononcology.ie/). Trained as an MD, he worked in experimental clinical research, pharmaceutical industry, and basic biological research. Before moving to Dublin in 2009 he held a Chair for Molecular Cell Biology at the University of Glasgow and was a Senior Group Leader at the Beatson Institute for Cancer Research in Glasgow, Scotland. He is best known for his work in oncogene signal transduction, proteomics, systems biology, and precision medicine. He is ranked No 2 in the world in precision oncology by citations. He has made salient

contributions to elucidating the function of the Raf kinases and the ERK pathway, and more recently to understand systems wide effects of oncogenes. His current research interest focuses on understanding molecular mechanisms of malignant transformation, network mediated drug resistance in cancer, and the construction of Digital Twins for personalized cancer diagnosis and therapy. He serves on several editorial boards and scientific advisory boards and is a Fellow of the Royal Society of Edinburgh and a Member of the Royal Irish Academy.

PERSONALISED MEDICINE PANEL: 10:15 AM - 11:30 AM

Dr Jane English

Principal Investigator, INFANT Research Centre, University College Cork

Dr Jane English, Lecturer in Anatomy and Neuroscience, has expertise in the application of proteomics, metabolomics and bioinformatics to improve our understanding of the molecular pathways implicated in maternal and child health/disease. Jane received her PhD in Molecular Psychiatry and Proteomics from the Royal College of Surgeons in Ireland (RCSI) and subsequently joined the M.J. Dunn laboratory as a post-doctoral researcher at the University College Dublin (UCD) Conway Institute, where she developed proteomic methods to study biologically relevant sub-proteomes in post-mortem brains from patients with Schizophrenia. Subsequently, Jane took on the role of Programme Manager for a HRB funded Biomarker Discovery Programme in Psychosis in the DR Cotter laboratory, RCSI. In this capacity, her research focused on using mass spectrometry based -discovery and -targeted workflows to identify and verify blood-based protein biomarkers which predict the onset of psychotic disorder in children with "at risk mental state". In 2017, Jane was awarded a Science Foundation Ireland - Industry Fellowship to gain industry experience in personalised diagnostics and the development of commercial biomarker assays at Inform Bioscience Ltd., Co. Cork. In 2018, Jane was awarded a prestigious Health Research Board -Emerging Investigator Award and is the Principal Investigator of a Biomarker Discovery Programme in Autism Spectrum Disorder, at INFANT. In 2018, Jane was appointed Lecturer in the Department of Anatomy and Neuroscience, UCC.

Professor Fergal O'Brien

Deputy Vice Chancellor for Research and Innovation, Royal College of Surgeons Irelan Professor Fergal O'Brien is Professor of Bioengineering & Regenerative Medicine, Direct Innovation, and Head of Tissue Engineering Research Group in RCSI, one of the largest

advanced biomaterials and tissue engineering/regenerative medicine research groups in Ireland. He is also a PI and Deputy Director of AMBER, the SFI Centre for advanced materials and bioengineering research. He is currently a member of the World Council of Biomechanics and immediate-past President of the Section of Bioengineering of the Royal Academy of Medicine in Ireland. In addition he is an editorial board member of 10 journals and was a founding editor for the Journal of the Mechanical Behavior of Biomedical Materials. He was Co-Chair of the World Congress of Biomechanics which brought over 4000 delegates to Ireland in 2018. He has published over 250 articles in leading peer-reviewed international journals, presented over 100 invited talks, filed numerous patents/disclosures resulting in the successful translation of technologies from his lab to regulatory approval and human clinical use and has supervised over 40 doctoral students to completion

Dr. Mark O'Sullivan

Postdoctoral Researcher, INFANT Research Centre, University College Cork

Dr. Mark O'Sullivan is a Postdoctoral Researcher in the Infant Research Centre in University
College Cork. Dr. O'Sullivan began in UCC in 2011 studying Electrical & Electronic Engineering completing a Masters degree, and returning to complete a PhD with the Infant Research
Centre in 2016. His PhD work focused on the development of novel technologies for newborn brain monitoring. Before completing the PhD in 2020, he began developing a business plan to commercialise aspects of his PhD research, resulting in a UCC Entrepreneur of the Year award and an Enterprise Ireland Student Entrepreneur of the Year award, followed by a fellowship with Techstars. Following the PhD, Dr. O'Sullivan continued as a Postdoctoral researcher investigating diagnostic decision support systems for fetal and newborn health and recently secured funding from Enterprise Ireland to

commercialise the Neurobell project which aims to develop a wireless brain monitor with integrated Al for automated detection of seizures in newborns.

Mr. David van Zuydam

Chief Executive Officer, Head Diagnostics

David is the Chief Executive Officer of the life sciences technology company, Head Diagnostics. Head Diagnostics is working to unleash the power of biomarkers through a handheld device that will aid the earlier detection and diagnosis of brain disease and injury such as Parkinson's. Parkinson's has long been regarded as a disease whereby symptoms present in the later stages leading to delayed diagnosis and treatment. David aims to tackle this anomaly directly with Head Diagnostics' non-invasive technology, and this revolutionary work has led to Head Diagnostics being listed in this year's list of 100 Hot Start-Ups.

Professor Aideen Sullivan

Head of Department of Anatomy and Neuroscience, University College Cork

Professor Aideen Sullivan is Head of the Department of Anatomy and Neuroscience in UCC. She is Academic Director of UCC's BSc in Medical and Health Sciences, a new research-lec multidisciplinary programme of which she led the development. Prior to that, Aideen was Academic Director of the BSc degree in Neuroscience since she arrived in UCC in 1998. Aideen's research activities are focused on the development of novel approaches to the treatment of

Aideen's research activities are focused on the development of novel approaches to the freatment of Parkinson's disease. She is an expert in investigating neuroprotective therapies, which have the potential to slow or reverse the progression of this debilitating disease. On this topic, she runs a collaborative research programme which has secured funding from a range of national and international organisations. Her research involves preclinical studies as well as patient-focused research. Her research on Parkinson's led her to be the founding Director of the Cork Parkinson's Disease Research Cluster and the vice- Director of the Cork NeuroScience Centre. She is passionate about public and patient engagement and outreach. She has led the organisation of several conferences and events on the topic of Parkinson's disease, often including patients and the public. She serves on editorial boards of several leading journals and grant-reviewing panels in the Neurosciences.





